AIRC-IG Rif.230522019 CERCHIA "DEVELOPMENT of innovative drug-loaded and aptamer targeted nanosystem for treatment of triple-negative breast cancer (DSB.AD001.157)

Area tematica

Scienze biomediche

Area progettuale

Struttura responsabile del progetto di ricerca

Istituto per l'endocrinologia e l'oncologia "Gaetano Salvatore" (IEOS)

Responsabile di progetto

LAURA CERCHIA
Telefono: 0815455751
E-mail: cerchia@unina.it

Abstract

The development of selective tumour targeting agents, which might ensure therapeutic applications, would greatly advance the development of personalized cancer therapy. We expect that the delivery of a potent chemotherapeutic drug and artificial small interfering RNA, entrapped into innovative aptamer-targeted nanosystems, in advanced preclinical models of TNBC will be predictive of clinical responses in human patients. Specifically, we envisage that the concomitant administration of cisplatin and siRNA targeting programmed cell death-ligand 1, a major feature of immune evasion in cancer cells, would promote synergistic therapeutic effects along with a reduction of toxic side effects. Aim of the project is the construction, validation and preclinical analysis of novel drug-loaded and aptamer targeted nanosystems for the selective treatment of TNBC. We intend to use aptamers selected in the previous AIRC grant (IG 18753) for both identifying novel actionable targets for TNBC and assembling a multicomponent nanovector to deliver chemotherapy and/or therapeutic siRNA, thus increasing the concentration at the tumour site while dispensing lower absolute doses of the drug.

Obiettivi

The project has the following objectives: 1) identification of novel TNBC targets, especially those that might impact chemotherapy resistance, which might be efficiently targeted by aptamer-nanosystems; 2) synthesis and characterization of novel polymeric nanomicelles as innovative platforms to carry and deliver therapeutic agents into TNBCs; 3) selection of best candidate nanovectors to be analysed in vivo in different animal models for tumour therapy; 4) bringing one (at least) or two final candidates to preclinical toxicity studies in order to be rapidly considered for human clinical trials.

Data inizio attività

02/01/2020

Parole chiave

Aptamers, nanovectors, TNBC

Ultimo aggiornamento: 02/01/2025